US-based healthcare companies Antidote Technologies and SEQSTER have partnered to improve participant identification and enrolment timelines for clinical trials.
The partnership aims to enhance enrolment outcomes for pharmaceutical and life science companies through the use of an integrated end-to-end solution.
Go deeper with GlobalData
SEQSTER’s operating system is designed to precisely match patients to trials using comprehensive data, including medical history, genomic information and lifestyle factors.
Using this solution alongside Antidote’s screening and patient support offerings is expected to expedite the recruitment process and enable high-quality matching of patients to trials.
The collaboration will merge SEQSTER’s data integration knowledge with Antidote’s wide-ranging partner network and contact centre for patient support to offer diversity in developing drugs.
The integration of technologies from both companies is expected to reduce the time required to initiate clinical trials, which is especially helpful for time-sensitive studies.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSEQSTER CEO and co-founder Ardy Arianpour said: “By integrating SEQSTER’s Operating System with Antidote’s precision recruitment capabilities, we are creating a powerful synergy that addresses one of the most pressing challenges in clinical research today: clinical trial recruitment plus engagement.
“This partnership empowers us to accelerate patient recruitment while providing a comprehensive, real-time view of study participant health data, accelerating the path to medical breakthroughs.”
Antidote’s approach involves connecting patients with researchers through a high-tech, high-touch method and a substantial global partnership network.
Antidote co-CEO Samantha Veeck said: “Partnering with SEQSTER allows us to enhance our precision recruitment process with unparalleled data integration capabilities, ensuring that we can more effectively identify suitable participants and reduce the time it takes to bring new treatments to market.
“Together with SEQSTER, we will transform the clinical trial landscape, making it more efficient, inclusive and patient-centred.”
Antidote and OneStudyTeam previously collaborated to offer an integrated, end-to-end patient referral management approach to sites and sponsors for added control in clinical trial patient recruitment.
